HC Wainwright & Co. Maintains Buy on Amylyx Pharma, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has maintained a Buy rating on Amylyx Pharma (NASDAQ:AMLX) but has significantly lowered the price target from $42 to $8. This adjustment reflects a substantial change in the valuation outlook for Amylyx Pharma.
March 12, 2024 | 10:43 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Amylyx Pharma's Buy rating is maintained by HC Wainwright & Co., but the price target is significantly reduced from $42 to $8.
The substantial reduction in the price target from $42 to $8 by a reputable analyst firm like HC Wainwright & Co. is likely to negatively impact investor sentiment towards Amylyx Pharma in the short term. This sharp decrease in the price target suggests a significant change in the expected performance or valuation of the company, which could lead to a decrease in stock price as investors adjust their expectations.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100